Peptides are often discussed in wellness and biohacking communities and are one of the fastest growing areas in integrative and functional medicine. However, not all peptides are created equal. Some are FDA-approved medications backed by large clinical trials, while others are experimental compounds with limited human data.
Understanding the difference is critical for making safe, informed decisions about your care.
The human body, and the bacteria in our bodies, produce thousands of peptides. Peptides are powerful, short chains of amino acids that act like signaling molecules in the body, supporting healing, metabolism, and hormone balance. Researchers have known about peptides for decades and over 60 are currently FDA approved for use [4]. In functional medicine, they’re gaining popularity for root-cause wellness, but not all are equal.
FDA-approved peptides undergo rigorous testing in large clinical trials for safety, dosing, and efficacy. The FDA ensures consistent manufacturing and monitors side effects.
Common examples:
• GLP-1 agonists (e.g., semaglutide/Ozempic® or tirzepatide/Zepbound®): Used for type 2 diabetes, sleep apnea, and weight loss by mimicking gut hormones to regulate blood sugar [1,2].
• Teriparatide (Forteo®): Builds bone for osteoporosis [3].
• Leuprolide(Lupron®): Hormone therapy for prostate cancer or endometriosis [3].
Non-FDA-approved peptides (compounded or research-grade) lack this oversight. They’re not tested in humans for specific uses and are sourced from laboratories or compounding pharmacies with variable purity and potency risks. Batch testing has shown a wide variety of potency and contamination between supplies.
Common types:
• BPC-157: Gut healing, tissue repair (investigational)
• Thymosin Beta-4: Wound healing, inflammation
• Ipamorelin/CJC-1295: Growth hormone support for anti-aging and muscle recovery
These peptides are sometimes used off-label in integrative clinics for longevity or injury support, but evidence remains preliminary. Many of the proposed benefits are extrapolated from rodent studies, and the long-term effects in humans remain largely unknown [5].
Approved peptides offer proven benefits with known risks. Non-approved peptides may help symptoms but can also carry risks related to contamination, adverse effects, inconsistent dosing, or unknown long-term outcomes.
For example, one proposed mechanism behind BPC-157 is angiogenesis, or new blood vessel formation. While angiogenesis may support healing, it may also theoretically increase cancer growth in certain settings.
Bottom Line —
Peptides are a promising and rapidly emerging area of medicine, and we expect to see many more become FDA-approved in the coming years [6]. However, the use of experimental, non-approved peptides carries meaningful risks.
At Carolina Total Wellness, we strive to guide patients toward evidence-based therapies and strategies that support health optimization without sacrificing safety.
References
- Musaimi OA, Shaer DA, et al. 2017 FDA peptide harvest. Pharmaceuticals. 2018.
- Musaimi OA, Shaer DA, et al. 2020 FDA tides (peptides and oligonucleotides) harvest. Pharmaceuticals. 2021.
- Zhang H, Chen S. Cyclic peptide drugs approved in the last two decades (2001–2021). 2021.
- Ji X, Nielsen AL, Heinis C. Cyclic peptides for drug development. 2023.
- Newman D, Cragg G. Natural products as sources of new drugs over the nearly four decades from 1981–2019. 2020.
- Papapetropoulos A, Topouzis S, et al. Novel drugs approved by the EMA, FDA, and MHRA in 2023. 2024.
- Gattu R, Ramesh SS, et al. Peptide-bioactive hybrid molecules in infectious disease therapeutics. 2023.
- Ayala-Aguilera CC, Valero T, et al. Small molecule kinase inhibitor drugs (1995–2021). 2021.
- Péczka N, Orgován Z, et al. Electrophilic warheads in covalent drug discovery. 2022.
- Dalton SE, Pietro OD, Hennessy E. FDA-approved small molecule drugs with covalent mechanisms of action. 2025.
Learn More
